Literature DB >> 28252813

Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients.

H Trattner1, S Blüml2, I Steiner3, U Plut1, S Radakovic1, A Tanew1.   

Abstract

BACKGROUND: Association of palmoplantar pustulosis (PPP) with metabolic and autoimmune diseases has been reported in mostly small case series or anecdotal cases.
OBJECTIVE: To assess health-related quality of life and prevalence of comorbidities in a large cohort of PPP patients.
METHODS: We conducted a cross-sectional study on patients with either active or past PPP. Disease severity was measured by the Palmoplantar Pustulosis Area and Severity Index (ppPASI). Quality of life was assessed by the Dermatology Life Quality Index (DLQI). Comorbidities were evaluated by medical history, blood examination, stool testing for Helicobacter pylori antigen and screening tools for depression and psoriatic arthritis.
RESULTS: A total of 102 patients (87 women, 15 men) with a mean age of 52.6 ± 14.1 years were evaluated. The mean DLQI was 7 ± 6. Comorbidities were frequent and consisted of hypercholesterolaemia (38%), hypertension (32%), obesity (27%), metabolic syndrome (26%), depression (24%), diabetes (19%), autoimmune thyroiditis (16%) and psoriatic arthritis (16%).
CONCLUSION: Patients with PPP have an impaired quality of life and a broad range of comorbidities. Contrary to other reports, our investigation failed to show an association between PPP and coeliac disease or H. pylori infection.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2017        PMID: 28252813     DOI: 10.1111/jdv.14187

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  Risks of Comorbidities in Patients With Palmoplantar Pustulosis vs Patients With Psoriasis Vulgaris or Pompholyx in Korea.

Authors:  Dong Hyo Kim; Jin Yong Lee; Soo Ick Cho; Seong Jin Jo
Journal:  JAMA Dermatol       Date:  2022-06-01       Impact factor: 11.816

2.  Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study.

Authors:  Celine Miyazaki; Rosarin Sruamsiri; Jӧrg Mahlich; Wonjoo Jung
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

Review 3.  Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments.

Authors:  Magdalena Misiak-Galazka; Joanna Zozula; Lidia Rudnicka
Journal:  Am J Clin Dermatol       Date:  2020-06       Impact factor: 7.403

4.  Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.

Authors:  Yukari Okubo; Hitomi Morishima; Richuan Zheng; Tadashi Terui
Journal:  J Dermatol       Date:  2021-08-28       Impact factor: 3.468

Review 5.  "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis.

Authors:  Ranjitha Uppala; Lam C Tsoi; Paul W Harms; Bo Wang; Allison C Billi; Emanual Maverakis; J Michelle Kahlenberg; Nicole L Ward; Johann E Gudjonsson
Journal:  Cell Mol Immunol       Date:  2020-08-19       Impact factor: 11.530

6.  Rapid induction of clinical remission in SAPHO syndrome using high-dose Tripterygium glycosides: A case report.

Authors:  Liang Gong; Lun Wang; Yihan Cao; Chen Li
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

7.  Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.

Authors:  T Yamamoto; K Fukuda; A Morita; T Kimura; H Morishima; R Goto; R Zheng; T Terui
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-15       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.